1. Home
  2. MGNX

as 05-30-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Founded: 2000 Country:
United States
United States
Employees: N/A City: Rockville
Market Cap: 97.2M IPO Year: 2013
Target Price: $5.33 AVG Volume (30 days): 378.7K
Analyst Decision: Hold Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.89 EPS Growth: N/A
52 Week Low/High: $0.99 - $5.77 Next Earning Date: 05-13-2025
Revenue: $154,050,000 Revenue Growth: 255.31%
Revenue Growth (this year): -69.28% Revenue Growth (next year): 45.52%

MGNX Daily Stock ML Predictions

Share on Social Networks: